Meta-analyses of prospective cohort studies reveal a sobering epidemiological finding: individuals with type 2 diabetes face a 2-3 times higher relative risk of developing dementia compared to non-diabetic peers. This substantial elevation in risk reflects the cumulative impact of dysregulated insulin signalling and chronic hyperglycaemia on brain structure and function. The mechanistic pathways responsible include cerebrovascular damage, neuroinflammatory cascades, and compromised neuronal energy production. However, recent pharmacological research offers a counterpoint to this bleak outlook. Emerging evidence indicates that select diabetes medications confer neuroprotective benefits independent of glucose control alone, suggesting novel preventive strategies may soon extend beyond conventional metabolic management.
Was this article helpful?
